Septerna’s (SEPN) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Septerna (NASDAQ:SEPN) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $50.00 target price on the stock.

Several other equities research analysts have also commented on SEPN. Wells Fargo & Company began coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price target on the stock. TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They issued a “buy” rating for the company. Finally, JPMorgan Chase & Co. initiated coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock.

Septerna Stock Down 13.6 %

Shares of NASDAQ SEPN opened at $11.38 on Tuesday. The company’s 50 day simple moving average is $20.17. Septerna has a 12 month low of $11.27 and a 12 month high of $28.99.

Institutional Investors Weigh In On Septerna

Several hedge funds have recently modified their holdings of the company. New York State Common Retirement Fund acquired a new position in Septerna in the 4th quarter worth about $32,000. PNC Financial Services Group Inc. acquired a new position in shares of Septerna during the 4th quarter worth approximately $61,000. SG Americas Securities LLC purchased a new position in shares of Septerna during the 4th quarter valued at approximately $185,000. Corebridge Financial Inc. acquired a new stake in Septerna in the 4th quarter valued at $212,000. Finally, M&T Bank Corp purchased a new stake in Septerna in the 4th quarter worth $376,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.